Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07UKJ
|
|||
| Former ID |
DNCL002162
|
|||
| Drug Name |
Enavatuzumab
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Company |
Abbott Laboratories
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | TNF superfamily receptor 12A (TNFRSF12A) | Target Info | . | [1] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Reactome | TNFR2 non-canonical NF-kB pathway | |||
| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | ||||
| WikiPathways | TWEAK Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Expression of TweakR in breast cancer and preclinical activity of enavatuzumab, a humanized anti-TweakR mAb. J Cancer Res Clin Oncol. 2013 Feb;139(2):315-25. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.